Vascular Dementia: Potential of Antiplatelet Agents in Prevention | Zendy

Hugues Chabriat | Zendy; M G Bousser | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vascular Dementia: Potential of Antiplatelet Agents in Prevention

Author(s) -

Hugues Chabriat,

M G Bousser

Publication year - 2006

Publication title -

european neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.573

H-Index - 77

eISSN - 1421-9913

pISSN - 0014-3022

DOI - 10.1159/000091981

Subject(s) - medicine , vascular dementia , dementia , hyperintensity , stroke (engine) , white matter , encephalopathy , cardiology , antithrombotic , occlusion , ischemia , leukoaraiosis , vascular disease , magnetic resonance imaging , radiology , disease , mechanical engineering , engineering

The term 'vascular dementia' (VaD) corresponds to a clinicoradiological syndrome that can be defined with more or less restriction. VaD can result from: (1) cortical or subcortical ischemic lesions related to the occlusion of large vessels, (2) lacunar infarcts with or without white-matter lesions at the subcortical level related to small-vessel diseases, (3) ischemic lesions related to hypoperfusion or anoxic-ischemic encephalopathy or (4) hemorrhagic lesions. The prevention of VaD is based on stroke prevention which implies risk factor manipulation and use of antithrombotic drugs among which the most widely used are antiplatelet drugs. The efficiency of these drugs to prevent cognitive impairment and dementia is not proven. Prospective studies are needed to investigate their potential in patients at risk of VaD: after ischemic stroke, in the presence of cognitive impairment of vascular origin or when MRI shows 'silent' ischemic white-matter lesions and/or infarcts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research